Global InformationLiraglutide information
 | |
 NMR structure of liraglutide. PDB entry 4apd | |
| Clinical data | |
|---|---|
| Trade names | Victoza, Saxenda, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611003 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.241.015 |
| Chemical and physical data | |
| Formula | C172H265N43O51 |
| Molar mass | 3751.262 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
Liraglutide, sold under the brand names Victoza and Saxenda among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity.[6][7] It is a second-line therapy for diabetes following first-line therapy with metformin.[6][8] Its effects on long-term health outcomes like heart disease and life expectancy are unclear.[6][9] It is given by injection under the skin.[6]
Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics.[6] It works by increasing insulin release from the pancreas and decreases excessive glucagon release.[6]
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection.[6][10] Gastrointestinal side-effects tend to be strongest at the beginning of treatment period and subside over time.[10] Other serious side effects may include angioedema, pancreatitis, gallbladder disease, and kidney problems.[6] Use in pregnancy and breastfeeding is of unclear safety.[6] A black box warning cautions that medullary thyroid cancers have been observed in rats treated with liraglutide, but it is "Unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as relevance to humans of such tumors in rodents has not been determined."[6]
Liraglutide was approved for medical use in the European Union in 2009, and in the United States in 2010.[4][11] In 2021, it was the 166th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[12][13]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Victoza- liraglutide injection". DailyMed. U.S. National Library of Medicine. Archived from the original on 27 March 2021. Retrieved 5 June 2021.
- ^ "Saxenda- liraglutide injection, solution". Archived from the original on 6 June 2021. Retrieved 5 June 2021.
- ^ a b "Victoza EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 23 March 2019. Retrieved 23 March 2019.
- ^ Cite error: The named reference
Saxenda EPARwas invoked but never defined (see the help page). - ^ a b c d e f g h i j "Liraglutide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 23 March 2019. Retrieved 23 March 2019.
- ^ "FDA approves weight management drug". U.S. Food and Drug Administration (FDA). 4 December 2020. Archived from the original on 14 June 2021. Retrieved 5 June 2021.
- ^ Shyangdan D, Cummins E, Royle P, Waugh N (May 2011). "Liraglutide for the treatment of type 2 diabetes". Health Technology Assessment. 15 (Suppl 1): 77–86. doi:10.3310/hta15Suppl1-09. PMID 21609656. Archived from the original on 14 March 2023. Retrieved 14 May 2023.
- ^ British National formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 685. ISBN 9780857113382.
- ^ a b Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A (October 2011). "Glucagon-like peptide analogues for type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews. 2011 (10): CD006423. doi:10.1002/14651858.cd006423.pub2. PMC 6486297. PMID 21975753.
- ^ "Liraglutide injection". DailyMed. U.S. National Library of Medicine. Archived from the original on 27 March 2021. Retrieved 23 March 2019.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Liraglutide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.